169 related articles for article (PubMed ID: 38707795)
1. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19.
Cheng FWT; Yan VKC; Wan EYF; Chui CSL; Lai FTT; Wong CKH; Li X; Zhang IR; Tang SCW; Wong ICK; Chan EWY
Kidney Int Rep; 2024 May; 9(5):1244-1253. PubMed ID: 38707795
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study.
Wan EYF; Yan VKC; Wong ZCT; Chui CSL; Lai FTT; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
EClinicalMedicine; 2023 Oct; 64():102225. PubMed ID: 37753272
[TBL] [Abstract][Full Text] [Related]
4. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
Chu WM; Wan EYF; Ting Wong ZC; Tam AR; Kei Wong IC; Yin Chan EW; Ngai Hung IF
EClinicalMedicine; 2024 Jun; 72():102620. PubMed ID: 38737003
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
7. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
10. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
medRxiv; 2022 Dec; ():. PubMed ID: 36561190
[TBL] [Abstract][Full Text] [Related]
12. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).
Yip TC; Lui GC; Lai MS; Wong VW; Tse YK; Ma BH; Hui E; Leung MKW; Chan HL; Hui DS; Wong GL
Clin Infect Dis; 2023 Feb; 76(3):e26-e33. PubMed ID: 36031408
[TBL] [Abstract][Full Text] [Related]
14. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.
Wai AK; Chan CY; Cheung AW; Wang K; Chan SC; Lee TT; Luk LY; Yip ET; Ho JW; Tsui OW; Cheung KW; Lee S; Tong CK; Yamamoto T; Rainer TH; Wong EL
Lancet Reg Health West Pac; 2023 Jan; 30():100602. PubMed ID: 36212676
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir.
Bai F; Beringheli T; Vitaletti V; Santoro A; Molà F; Copes A; Gemignani N; Pettenuzzo S; Castoldi R; Varisco B; Nardo R; Lundgren LB; Ligresti R; Sala M; Albertini L; Augello M; Biasioli L; Bono V; Rovito R; Bini T; Passarella S; Orfeo NV; Monforte AD; Marchetti G
Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38829439
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
Park JJ; Kim H; Kim YK; Lee SS; Jung E; Lee JS; Lee J
J Korean Med Sci; 2023 Oct; 38(42):e347. PubMed ID: 37904658
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
[TBL] [Abstract][Full Text] [Related]
19. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P
J Antimicrob Chemother; 2024 May; ():. PubMed ID: 38817046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
